Clinical trials: Patients With Schizophrenia-like Disorders
Schizophrenia, Mental Disorders
Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients
The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it would be a turning point in drug therapy.
- Conditions
- Schizophrenia, Mental Disorders, Psychotic Disorders
- Trial name
- PAFIP_TLR (NCT02897167)
- Testing
- Retrospective study of frozen samples, Prospective study of fresh samples
- Where
- Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Patients With Schizophrenia-like Disorders
Interest of the Tool: Evaluation of Specific Care in an Ecological Environment for Patients Suffering From Schizophrenia-like Disorders
The study use a new ecological questionnaire called ESSME developed by a care team in order to evaluate ecological environment of patients with schizophrenia-like disorders.
- Trial name
- IEvaEcoSchi (NCT05349513)
- Testing
- ESSME questionnaire
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier Henri Laborit
Metabolic Disturbance, Schizophrenia
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Background and objective: Clozapine and olanzapine are some of the most effective antipsychotic drugs, but unfortunately, both drugs induce weight gain and conveys a high degree of metabolic disturbances.
- Conditions
- Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine
- Trial name
- NCT04892199
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- 3 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci